Mark Cragg graduated from Bath University in 1994 with a first class degree in Biochemistry following two successful placements at Glaxo WellcomeMark Cragg graduated from Bath University in 1994 with a first class degree in Biochemistry following two successful placements at Glaxo Wellcome and Northeastern University, Boston. He then moved to Southampton, undertaking a PhD in Immunology and Immunochemistry in the Cancer Sciences Unit (CSU). Following his PhD, he was awarded a career track fellowship within the School of Medicine and subsequently obtained a prestigious fellowship with the Leukaemia Research Fund (now Leukaemia and Lymphoma Research). This fellowship involved a period of study in the world-class laboratory of Andreas Strasser at the Walter and Eliza Hall institute in Melbourne. He returned to the UK in 2007, to establish his own research group within the CSU.
His research group is interested in how targeted therapeutics result in tumour regression. The research is currently focused on two main types of therapeutics - antibodies and oncogenic kinase inhibitors with the aim of understanding how these therapeutics function to delete tumour cells and how they might be augmented. Throughout the strategy undertaken by the group is highly translational with iterative cycling between in vitro experiments, appropriate in vivo model systems and primary clinical material.